Autonomous Healthcare Awarded DARPA Contract to Develop Hemorrhage Control Technology

Estimated reading time: Less than a minute

Autonomous Healthcare, Inc. has been awarded a Small Business Innovation Research (SBIR) Phase I contract by the Defense Advanced Research Projects Agency (DARPA) to commercialize an automated system for hemorrhage control and resuscitation at the point of injury.

Non-compressible torso hemorrhage, which results from bleeding that cannot be controlled with a tourniquet or application of direct pressure, is the leading cause of death among survivable battlefield injuries. Additionally, within the civilian US sectors, bleeding from trauma creates a significant death toll among survivable injuries. Autonomous Healthcare aims to develop a technology that will provide fully-automated partial resuscitative endovascular balloon occlusion of the aorta (pREBOA), allowing a set amount of blood past the balloon and mitigating the ischemia-reperfusion metabolic injury.

"This award provides further validation for Autonomous Healthcare's vision to revolutionize emergency and critical care by introducing closed-loop control technologies," said Dr. Behnood Gholami, Co-Founder and CEO of Autonomous Healthcare.  "An automated system to provide pREBOA will create a better opportunity for use in trauma scenarios as well as make the procedure more widely available to medics and first responders."